Zobrazeno 1 - 10
of 85
pro vyhledávání: '"Stefan Boes"'
Autor:
Bruno Fuchs, Beata Bode, Philip Heesen, Barbara Kopf, Christian Michelitsch, Manfred Odermatt, Pietro Giovanoli, Stefan Breitenstein, Paul Schneider, Guido Schüpfer, Stefan Boes, Gabriela Studer
Publikováno v:
Swiss Medical Weekly, Vol 154, Iss 4 (2024)
No abstract available.
Externí odkaz:
https://doaj.org/article/fc945c538d6945ef837507263501e75f
Autor:
Alice Giese, Rasheda Khanam, Son Nghiem, Anthony Staines, Thomas Rosemann, Stefan Boes, Michael M Havranek
Publikováno v:
PLoS ONE, Vol 19, Iss 2, p e0285285 (2024)
There currently exists no comprehensive and up-to date overview on the financial impact of the different adverse events covered by the Patient Safety Indicators (PSIs) from the Agency for Healthcare Research and Quality. We conducted a retrospective
Externí odkaz:
https://doaj.org/article/04b4c1bf61ac4126aedead248689f1bb
Autor:
Daniel Wehrli, Hans Gilljam, Dow Mu Koh, Simon Matoori, Thomas Sartoretti, Stefan Boes, Martin Hartmann, Katharina Roser, Alexander Ort, Philippe Wanner, Dorothee Harder, Rasmus Bech-Hohenberger, Johannes M. Froehlich, Georg Marcus Fröhlich, Jochen Mutschler, Tino Plümecke, Andreas Gutzeit
Publikováno v:
Frontiers in Psychiatry, Vol 14 (2023)
BackgroundSwitzerland ranks among the top three healthcare systems in the world with regards to healthcare access, suggesting a high degree of health equity. However, Switzerland has few preventive strategies against smoking abuse. The aim of this st
Externí odkaz:
https://doaj.org/article/aaedfb845c8f48a6865b481f6b597620
Publikováno v:
BMJ Open, Vol 13, Iss 11 (2023)
Objectives Biological products have contributed to extraordinary advances in disease treatments over the last decade. However, the cost-saving potential of imitator products, so-called biosimilars, is still under-researched in Switzerland. This study
Externí odkaz:
https://doaj.org/article/0cac6a7f1f994048a0b414406bd94f85
Publikováno v:
BMJ Open, Vol 13, Iss 3 (2023)
Objectives The optimal use of opioids after knee replacement (KR) remains to be determined, given the growing evidence that opioids are no more effective than other analgesics and that their adverse effects can impair quality of life. Therefore, the
Externí odkaz:
https://doaj.org/article/5e8a109b49fe4611b0766bed2f37c5f0
Autor:
Roderick Skinner, Leontien C M Kremer, Anne Blondeel, Samira Essiaf, Gisela Michel, Tomas Kepak, Riccardo Haupt, Jeanette F Winther, Lars Hjorth, Joke C Korevaar, Saskia M F Pluijm, Katharina Roser, Mieke Rijken, Renée L Mulder, Helena J H van der Pal, Rosella P M G Hermens, Stefan Boes, Rebecca J van Kalsbeek, Monica Muraca, Katerina Kepakova, Line E Frederiksen, Anita Kienesberger, Jacqueline J Loonen, Kylie B O'Brien, Marleen Renard, Anne Uyttebroeck, Cecilia Follin
Publikováno v:
BMJ Open, Vol 12, Iss 11 (2022)
Introduction Long-term survival after childhood cancer often comes at the expense of late, adverse health conditions. However, survivorship care is frequently not available for adult survivors in Europe. The PanCareFollowUp Consortium therefore devel
Externí odkaz:
https://doaj.org/article/b3d576127664449990a862a9ed350b41
Publikováno v:
BMC Health Services Research, Vol 21, Iss 1, Pp 1-18 (2021)
Abstract Background A hospitalization phase represents a challenge to medication safety especially for multimorbid patients as acute medical needs might interact with pre-existing medications or evoke adverse drug effects. This project aimed to exami
Externí odkaz:
https://doaj.org/article/3a8e6007fc494a40b3a5543aa06e0193
Publikováno v:
BMC Public Health, Vol 21, Iss 1, Pp 1-15 (2021)
Abstract Background Inequalities in health care use between immigrants and non-migrants are an important issue in many countries, with potentially negative effects on population health and welfare. The aim of this study is to understand the factors t
Externí odkaz:
https://doaj.org/article/568dff768c2c410db3c0eef0440767d6
Autor:
Dominik J. Wettstein, Stefan Boes
Publikováno v:
BMC Health Services Research, Vol 21, Iss 1, Pp 1-18 (2021)
Abstract Background Price negotiations for specialty pharmaceuticals take place in a complex market setting. The determination of the added value of new treatments and the related societal willingness to pay are of increasing importance in policy ref
Externí odkaz:
https://doaj.org/article/5e3ee6f522ff4c69b9aa103a1448d3e5
Autor:
Dominik J. Wettstein, Stefan Boes
Publikováno v:
Health Economics Review, Vol 10, Iss 1, Pp 1-15 (2020)
Abstract Background The necessity to measure and reward “value for money” of new pharmaceuticals has become central in health policy debates, as much as the requirement to assess the “willingness to pay” for an additional, quality-adjusted li
Externí odkaz:
https://doaj.org/article/299b86e5fbc5474c95195d6f92b1d672